AstraZeneca expects new drugs and a recent diabetes deal to offset a wave of patent expiries and return it to growth faster than analysts predict, with 2017 revenue likely to be broadly in line with the 2013 level. The company’s forecast implies a potential $3 billion upgrade to the consensus estimate from analysts and marks an attempt to call a bottom to a sales decline driven by the loss of exclusivity on several top-selling medicines. Britain’s second-biggest drugmaker is already suffering from generic competition to its antipsychotic Seroquel, while its Nexium treatment for excess stomach acid loses U.S. patent cover this year.
Help employers find you! Check out all the jobs and post your resume.
